ResMed Inc. (NYSE:RMD – Free Report) – Equities researchers at Zacks Research lowered their Q4 2026 earnings per share (EPS) estimates for shares of ResMed in a report issued on Wednesday, February 19th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $2.48 for the quarter, down from their previous forecast of $2.49. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share.
A number of other brokerages have also commented on RMD. Piper Sandler upped their price objective on ResMed from $252.00 to $260.00 and gave the company a “neutral” rating in a report on Friday, January 31st. The Goldman Sachs Group initiated coverage on shares of ResMed in a research note on Thursday, January 16th. They issued a “buy” rating on the stock. KeyCorp lifted their price objective on shares of ResMed from $266.00 to $280.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. JPMorgan Chase & Co. increased their target price on shares of ResMed from $270.00 to $286.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a report on Friday, January 31st. One analyst has rated the stock with a sell rating, six have issued a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, ResMed has a consensus rating of “Moderate Buy” and a consensus price target of $244.73.
ResMed Trading Up 2.6 %
Shares of NYSE:RMD opened at $235.73 on Monday. ResMed has a 12-month low of $170.56 and a 12-month high of $263.05. The business has a 50 day moving average of $237.06 and a 200-day moving average of $239.66. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The stock has a market cap of $34.62 billion, a PE ratio of 27.83, a P/E/G ratio of 1.53 and a beta of 0.70.
ResMed (NYSE:RMD – Get Free Report) last announced its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.
Institutional Trading of ResMed
Hedge funds have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC boosted its holdings in shares of ResMed by 24,311.9% during the 3rd quarter. International Assets Investment Management LLC now owns 26,609 shares of the medical equipment provider’s stock valued at $6,496,000 after acquiring an additional 26,500 shares in the last quarter. Assenagon Asset Management S.A. raised its position in ResMed by 46.0% in the third quarter. Assenagon Asset Management S.A. now owns 48,931 shares of the medical equipment provider’s stock valued at $11,945,000 after purchasing an additional 15,424 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of ResMed by 31.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,254 shares of the medical equipment provider’s stock valued at $2,212,000 after purchasing an additional 2,212 shares in the last quarter. Forsta AP Fonden grew its holdings in shares of ResMed by 111.6% during the third quarter. Forsta AP Fonden now owns 56,700 shares of the medical equipment provider’s stock worth $13,842,000 after purchasing an additional 29,900 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of ResMed by 35.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 7,271 shares of the medical equipment provider’s stock valued at $1,775,000 after buying an additional 1,893 shares during the period. Institutional investors and hedge funds own 54.98% of the company’s stock.
Insider Transactions at ResMed
In other ResMed news, CEO Michael J. Farrell sold 8,009 shares of ResMed stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $236.77, for a total value of $1,896,290.93. Following the transaction, the chief executive officer now owns 455,472 shares in the company, valued at $107,842,105.44. The trade was a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the transaction, the director now directly owns 77,218 shares of the company’s stock, valued at approximately $18,695,249.98. The trade was a 2.52 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,147 shares of company stock valued at $2,905,745. Corporate insiders own 0.71% of the company’s stock.
ResMed Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be paid a $0.53 dividend. The ex-dividend date is Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.90%. ResMed’s payout ratio is 25.03%.
ResMed Company Profile
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Read More
- Five stocks we like better than ResMed
- How to Choose Top Rated Stocks
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- The How And Why of Investing in Oil Stocks
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.